pcn poster

Posters

Obstructive Sleep Apnea and Risk of Motor Vehicle Accidents

Introduction: Previous studies have documented increased risk of motor vehicle accidents (MVAs) in patients with obstructive sleep apnea (OSA); however, clinical practices for diagnosing/...

Gaia S. Pocobelli , PhD;

Joanna Eavey , MSPH;

Mary A. Akosile , MPH, MS;

Robert D. Wellman , MS;

Ron L. Johnson , MA;

Morgan Bron , PharmD, MS;

Ginger Carls , PhD;

Sascha Dublin , MD, PhD;

10/25/2020

Fremanezumab for the Prevention of Chronic Migraine in Patients with Comorbid Depression: A Pooled Analysis of Phase 3 Studies

Objective: A pooled analysis evaluated reductions in migraine and headache days among chronic migraine (CM) patients with comorbid depression (scores ≥10 on the 9-item Patient Health Ques...

Dawn Buse ;

Xiaoping Ning ;

Ronghua Yang ;

Verena Ramirez-Campos ;

Richard Lipton , MD;

Joshua P. Cohen , PhD;

10/25/2020

Task-assisted, bilateral, repetitive Transcranial Magnetic Stimulation improves verbal memory and executive function in Treatment Resistant Depression: Case Report

Background: Treatment-resistant depression (TRD) is a relatively common occurrence in clinical practice, with up to 50% to 60% of patients not achieving adequate response following antide...

Bassem Saad , MD;

Carly Brin ;

Nicholas Mischel , MD, PhD;

Daniel Amarasinghe , BS;

10/21/2020

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

Leslie Citrome , MD;

Laura Morrison , MPH;

John J. Sheehan , PhD, MBA, RPh;

Carmine Rossi , PhD;

Maryia Zhdanava , MA;

Oliver Lopena , PharmD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Swapna Karkare , MS;

10/19/2020

A Telehealth Literacy Screening Tool for Patients with Psychosocial Barriers

Background: The benefits of telehealth from a social, financial, and practical sense are well established. However, there are many gaps in the literature regarding telemedicine services i...

Diab Ali ;

10/19/2020

Deutetrabenazine Reduces Severe Tardive Dyskinesia Movements in a 3-year Open-Label Extension Trial

Background: There are no established treatment guidelines for tardive dyskinesia (TD) based on movement severity. The 12-week ARM-TD and AIM-TD studies in TD patients with baseline Abnorm...

Joseph Bona , MD;

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Nayla Chaijale , PhD;

Mark Forrest Gordon , MD;

10/18/2020

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...

Leslie Lundt , MD;

Chuck Yonan , PharmD;

Rahul Dhanda , PhD;

Jonathan Meyer , MD;

Betsy Benning ;

Ericha Franey , PhD;

Edward Goldberg , MD;

10/18/2020

Safety and Tolerability of Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Treatment of Schizophrenia in the ALPINE Study

Objective: Evaluate safety and tolerability of an aripiprazole lauroxil (AL) 2-month regimen using 1-day initiation in patients hospitalized for acute exacerbation of schizophrenia and tr...

Ilda Bidollari , MD, MBA;

Alexa Vasios , MS, MPH;

Amy Claxton , PhD;

10/08/2020

Post Hoc Analyses of Treatment History on SHP465 Mixed Amphetamine Salts Extended-Release Responses in Adult Attention-Deficit/Hyperactivity Disorder

In 2 placebo-controlled studies of adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Sca...

Valerie Arnold , MD;

Eric Lloyd , MS;

Salah Foraida , MD, MS;

10/08/2020

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...

Ken Yu , MS;

Holly Johnson , PhD;

Krystal Brown , PhD;

Michael Jablonski , PhD;

Bryan Dechairo , PhD;

Lisa Brown , PhD;

Oliver Vranjkovic , PhD;

James Li , MS, PhD;

10/08/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products